MIAMI / Apr 16, 2024 / Business Wire / Ontrak, Inc. (NASDAQ: OTRK) (“Ontrak” or the “Company”), a leading AI-powered and telehealth-enabled healthcare company, today reported its financial results for the fourth quarter and year ended December 31, 2023.
Management Commentary
“In addition to new business development efforts, we focused this quarter on continued innovation with a technology focus. We introduced our Advanced Engagement System to offer increased efficiencies and higher ROI, while maintaining a patient-centered focus amidst a challenging macro environment facing our health plan partners,” said Brandon LaVerne, the Company's Chief Executive Officer and Chief Operating Officer. “Our WholeHealth+ program is incredibly important and aligned to help solve for these macro issues by delivering proven health outcomes and reducing costs while also increasing engagement, leading to increased quality scores. We are confident in our value-proposition to health plan partners, and are seeing continued demand in our recent customer expansions and further progress in our pipeline as a result.”
Fourth Quarter 2023 Financial Results Highlights
Adjusted EBITDA, non-GAAP net loss and non-GAAP diluted net loss per common share are non-GAAP financial measures. See our description and reconciliation of such non-GAAP measures at the end of this release.
Fiscal Year 2023 Financial Results Highlights
Fourth Quarter 2023 and Recent Operating Highlights
Financial Outlook
The following outlook is based on information available as of the date of this press release and is subject to change in the future.
For the quarter ending March 31, 2024, the Company estimates revenue in the range of $2.5 million to $2.9 million.
Conference Call & Webcast Details
The Company will host a conference call/webcast today at 4:30 pm ET/1:30 pm PT. Investors, analysts, employees and the general public can access the call by registering online for dial-in information or via live audio webcast at: https://ontrakhealth.com/investors/presentations-events. Participants interested in dialing in to the conference call are requested to register a day in advance or at a minimum 15 minutes before the start of the call to obtain a unique pin for the call.
A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
About Ontrak, Inc.
Ontrak Health (NASDAQ: OTRK) is a leading AI and telehealth-enabled healthcare company, whose mission is to help improve the health and save the lives of as many people as possible. Ontrak identifies, engages, activates, and provides care pathways to treatment for the most vulnerable members of the behavioral health population who would otherwise fall through the cracks of the healthcare system. We engage individuals with anxiety, depression, substance use disorder and chronic disease through personalized care coaching and customized care pathways that help them receive the treatment and advocacy they need, despite the socio-economic, medical and health system barriers that exacerbate the severity of their comorbid illnesses. The company’s integrated intervention platform uses AI, predictive analytics and digital interfaces combined with dozens of care coach engagements to deliver improved member health, better healthcare system utilization, and durable outcomes and savings to healthcare payors.
Learn more at www.ontrakhealth.com
Forward-Looking Statements
This press release contains “forward-looking” statements that are based on the Company’s beliefs and assumptions and on information currently available to the Company on the date of this press release and are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “may,” “will,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plan,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” or the negative of those words or other comparable words. Forward-looking statements may include, but are not limited to, the expectations around state approval and timing of launch of the new customer contract, the Company’s belief that its strategy will accelerate the Company’s return to growth, maximize the Company’s differentiated platform, and strengthen the Company’s position, the Company’s expectations regarding reductions in costs resulting from its cost saving measures, and the Company’s estimated revenue for 2023. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements, including, without limitation, risks related to: the Company’s ability to successfully execute on its strategy and business plan; the Company’s ability to increase its revenue and efficiently manage expenses and achieve profitability; the Company’s high customer concentration and the ability of its customers to terminate their contracts for convenience; the adequacy of the Company’s existing cash resources and anticipated capital commitments and future cash requirements to enable the Company to continue as a going concern; the Company’s ability to raise additional capital when needed; difficulty enrolling new members and maintaining existing members in the Company’s programs; the effectiveness of the Company’s treatment programs; lower than anticipated eligible members under the Company’s contracts; the Company’s dependence on key personnel and the Company’s ability to recruit and retain key personnel; the Company’s ability to maintain the listing of its stock on Nasdaq; the outcomes of ongoing legal proceedings brought by the U.S. Department of Justice and the Securities and Exchange Commission against the Company’s largest stockholder and former Chief Executive Officer and Chairman, and whether governmental authorities will institute separate investigations or proceedings against the Company and/or its current or former executives and/or directors; substantial regulation in the health care industry; changes in regulations or issuance of new regulations or interpretations; the Company’s limited operating history; difficulty in developing, exploiting and protecting proprietary technologies; business disruption and related risks; general economic conditions, nationally and globally, and their effect on the market for our service; intense competition and competitive pressures and trends in the Company’s industry and the Company’s ability to successfully compete; changes in laws, regulations, or policies; and risks related to the Company’s ability to realize the potential benefits of and to effectively integrate acquisitions. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company’s most recent Securities and Exchange Commission filings which are available on its website at http://www.sec.gov. Forward-looking statements are current only as of the date they are made and the Company assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Non-GAAP Financial Measures
To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles, or GAAP, the Company has provided in this press release and the quarterly conference call held on the date hereof certain non-GAAP financial measures. The non-GAAP financial measures presented include EBITDA, Adjusted EBITDA, Non-GAAP net loss, and Non-GAAP net loss per common share, which are not U.S. GAAP financial measures. We believe that the presentation of these financial measures enhances an investor’s understanding of our financial performance. We further believe that these financial measures are useful financial metrics to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business.
EBITDA consists of net loss before interest, taxes, depreciation and amortization expenses. Adjusted EBITDA consists of net loss before interest, taxes, depreciation, amortization, stock-based compensation, write-off of debt issuance costs, write-off of other assets, restructuring, severance and related costs, gain on termination of operating lease, and gain/loss on change in fair value of warrant liability. We believe that making such adjustments provides investors meaningful information to understand our results of operations and the ability to analyze our financial and business trends on a period-to-period basis.
Non-GAAP net loss consists of net loss adjusted for stock-based compensation, write-off of debt issuance costs, write-off of other assets, restructuring, severance and related costs, gain on termination of operating lease and gain/loss on change in fair value of warrant liability. Non-GAAP net loss per common share consists of loss per share adjusted for non-GAAP net loss attributable to common stockholders. We believe that making such adjustments provides investors meaningful information to understand our results of operations and the ability to analyze our financial and business trends on a period-to-period basis.
We believe the above non-GAAP financial measures are commonly used by investors to evaluate our performance and that of our competitors. However, our use of the term EBITDA, Adjusted EBITDA, Non-GAAP net loss and Non-GAAP net loss per common share may vary from that of others in our industry. None of EBITDA, Adjusted EBITDA, Non-GAAP net loss or Non-GAAP net loss per common share should be considered as an alternative to net loss before taxes, net loss, net loss per common share or any other performance measures derived in accordance with U.S. GAAP as measures of performance.
See the Reconciliation of Non-GAAP Measures table at the end of this press release for a reconciliation of the Non-GAAP financial measures to U.S. GAAP financial measures.
ONTRAK, INC. | |||||||||||||||
| Three Months Ended |
| Year Ended | ||||||||||||
| 2023 |
| 2022 |
| 2023 |
| 2022 | ||||||||
Revenue | $ | 3,539 |
|
| $ | 2,510 |
|
| $ | 12,743 |
|
| $ | 14,514 |
|
Cost of revenue |
| 1,252 |
|
|
| 973 |
|
|
| 3,943 |
|
|
| 7,461 |
|
Gross profit | $ | 2,287 |
|
| $ | 1,537 |
|
| $ | 8,800 |
|
| $ | 7,053 |
|
|
|
|
|
|
|
|
| ||||||||
Operating expenses: |
|
|
|
|
|
|
| ||||||||
Research and development |
| 1,893 |
|
|
| 1,861 |
|
|
| 6,626 |
|
|
| 10,974 |
|
Sales and marketing |
| 931 |
|
|
| 1,113 |
|
|
| 3,580 |
|
|
| 5,006 |
|
General and administrative |
| 4,676 |
|
|
| 6,562 |
|
|
| 19,269 |
|
|
| 34,256 |
|
Restructuring, severance and related charges |
| — |
|
|
| — |
|
|
| 457 |
|
|
| 934 |
|
Total operating expenses |
| 7,500 |
|
|
| 9,536 |
|
|
| 29,932 |
|
|
| 51,170 |
|
Operating loss |
| (5,213 | ) |
|
| (7,999 | ) |
|
| (21,132 | ) |
|
| (44,117 | ) |
|
|
|
|
|
|
|
| ||||||||
Other income (expense), net |
| 10 |
|
|
| (248 | ) |
|
| 334 |
|
|
| (3,461 | ) |
Interest expense, net |
| (1,193 | ) |
|
| (911 | ) |
|
| (7,202 | ) |
|
| (3,907 | ) |
Loss before income taxes |
| (6,396 | ) |
|
| (9,158 | ) |
|
| (28,000 | ) |
|
| (51,485 | ) |
Income tax benefit (expense) |
| — |
|
|
| 52 |
|
|
| 80 |
|
|
| (88 | ) |
Net loss |
| (6,396 | ) |
|
| (9,106 | ) |
|
| (27,920 | ) |
|
| (51,573 | ) |
Dividends on preferred stock - declared and undeclared |
| (2,238 | ) |
|
| (2,238 | ) |
|
| (8,954 | ) |
|
| (8,954 | ) |
Net loss attributable to common stockholders | $ | (8,634 | ) |
| $ | (11,344 | ) |
| $ | (36,874 | ) |
| $ | (60,527 | ) |
|
|
|
|
|
|
|
| ||||||||
Net loss per common share, basic and diluted | $ | (0.29 | ) |
| $ | (2.52 | ) |
| $ | (3.30 | ) |
| $ | (15.61 | ) |
|
|
|
|
|
|
|
| ||||||||
Weighted-average common shares outstanding, basic and diluted |
| 29,950 |
|
|
| 4,505 |
|
|
| 11,159 |
|
|
| 3,877 |
|
ONTRAK, INC. | |||||||
| December 31, | ||||||
| 2023 |
| 2022 | ||||
Assets |
|
|
| ||||
Current assets: |
|
|
| ||||
Cash | $ | 9,701 |
|
| $ | 5,032 |
|
Restricted cash - current |
| — |
|
|
| 4,477 |
|
Receivables, net |
| — |
|
|
| 973 |
|
Unbilled receivables |
| 207 |
|
|
| 453 |
|
Deferred costs - current |
| 128 |
|
|
| 156 |
|
Prepaid expenses and other current assets |
| 2,743 |
|
|
| 3,168 |
|
Total current assets |
| 12,779 |
|
|
| 14,259 |
|
Long-term assets: |
|
|
| ||||
Property and equipment, net |
| 913 |
|
|
| 2,498 |
|
Restricted cash - long-term |
| — |
|
|
| 204 |
|
Goodwill |
| 5,713 |
|
|
| 5,713 |
|
Intangible assets, net |
| 99 |
|
|
| 1,125 |
|
Other assets |
| 147 |
|
|
| 1,326 |
|
Operating lease right-of-use assets |
| 195 |
|
|
| 632 |
|
Total assets | $ | 19,846 |
|
| $ | 25,757 |
|
|
|
|
| ||||
Liabilities and stockholders' equity |
|
|
| ||||
Current liabilities: |
|
|
| ||||
Accounts payable | $ | 563 |
|
| $ | 1,927 |
|
Accrued compensation and benefits |
| 442 |
|
|
| 1,987 |
|
Deferred revenue |
| 97 |
|
|
| 326 |
|
Current portion of operating lease liabilities |
| 56 |
|
|
| 653 |
|
Other accrued liabilities |
| 2,784 |
|
|
| 4,576 |
|
Total current liabilities |
| 3,942 |
|
|
| 9,469 |
|
Long-term liabilities: |
|
|
| ||||
Long-term debt, net |
| 1,467 |
|
|
| 10,065 |
|
Long-term operating lease liabilities |
| 166 |
|
|
| 546 |
|
Total liabilities |
| 5,575 |
|
|
| 20,080 |
|
Commitments and contingencies |
|
|
| ||||
|
|
|
| ||||
Stockholders' equity: |
|
|
| ||||
Preferred stock, $0.0001 par value; 50,000,000 shares authorized; 3,770,265 shares issued and outstanding at each of December 31, 2023 and 2022 |
| — |
|
|
| — |
|
Common stock, $0.0001 par value, 500,000,000 shares authorized; 38,466,979 and 4,527,914 shares issued and outstanding at December 31, 2023 and 2022, respectively |
| 6 |
|
|
| 3 |
|
Additional paid-in capital |
| 484,926 |
|
|
| 448,415 |
|
Accumulated deficit |
| (470,661 | ) |
|
| (442,741 | ) |
Total stockholders' equity |
| 14,271 |
|
|
| 5,677 |
|
Total liabilities and stockholders' equity | $ | 19,846 |
|
| $ | 25,757 |
|
ONTRAK, INC. | |||||||
| Year Ended December 31, | ||||||
| 2023 |
| 2022 | ||||
Cash flows from operating activities |
|
|
| ||||
Net loss | $ | (27,920 | ) |
| $ | (51,573 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
| ||||
Stock-based compensation expense |
| 2,948 |
|
|
| 7,532 |
|
Write-off of debt issuance costs |
| — |
|
|
| 3,334 |
|
Paid-in-kind interest expense |
| 3,753 |
|
|
| 553 |
|
Bad debt expense |
| 531 |
|
|
| — |
|
Gain on termination of operating lease |
| (471 | ) |
|
| — |
|
Write-off of other asset |
| 100 |
|
|
| 259 |
|
Depreciation expense |
| 1,801 |
|
|
| 2,494 |
|
Amortization expense |
| 4,581 |
|
|
| 2,706 |
|
Change in fair value of warrants |
| (35 | ) |
|
| (133 | ) |
401(k) employer match in common shares |
| — |
|
|
| 628 |
|
Common stock issued for consulting services |
| — |
|
|
| 102 |
|
Changes in operating assets and liabilities: |
|
|
| ||||
Receivables |
| 972 |
|
|
| 4,965 |
|
Unbilled receivables |
| (285 | ) |
|
| 2,781 |
|
Prepaid and other assets |
| 668 |
|
|
| 1,558 |
|
Accounts payable |
| (1,179 | ) |
|
| 791 |
|
Deferred revenue |
| (229 | ) |
|
| (115 | ) |
Lease liabilities |
| (166 | ) |
|
| (328 | ) |
Other accrued liabilities |
| (567 | ) |
|
| 480 |
|
Net cash used in operating activities |
| (15,498 | ) |
|
| (23,966 | ) |
Cash flows from investing activities |
|
|
| ||||
Purchases of property and equipment |
| (285 | ) |
|
| (1,156 | ) |
Net cash used in investing activities |
| (285 | ) |
|
| (1,156 | ) |
|
|
|
| ||||
Cash flows from financing activities |
|
|
| ||||
Proceeds from Keep Well Notes |
| 8,000 |
|
|
| 11,000 |
|
Proceeds from Keep Well Agreement held in escrow and funded Private Placement |
| 6,000 |
|
|
| — |
|
Common stock, Pre-Funded Warrants and Warrants issued in Public Offering |
| 6,299 |
|
|
| — |
|
Financing transaction costs |
| (1,744 | ) |
|
| (907 | ) |
Repayment of 2024 Notes |
| — |
|
|
| (39,194 | ) |
Proceeds from issuance of common stock |
| — |
|
|
| 4,000 |
|
Common stock issuance costs |
| — |
|
|
| (706 | ) |
Financed insurance premium payments |
| (2,647 | ) |
|
| (2,777 | ) |
Finance lease obligations |
| (134 | ) |
|
| (282 | ) |
Dividends paid |
| — |
|
|
| (2,239 | ) |
Payment of taxes related to net-settled stock awards |
| (3 | ) |
|
| (6 | ) |
Net cash provided by (used in) financing activities |
| 15,771 |
|
|
| (31,111 | ) |
|
|
|
| ||||
Net change in cash and restricted cash |
| (12 | ) |
|
| (56,233 | ) |
Cash and restricted cash at beginning of period |
| 9,713 |
|
|
| 65,946 |
|
Cash and restricted cash at end of period | $ | 9,701 |
|
| $ | 9,713 |
|
|
|
|
| ||||
|
|
|
| ||||
Supplemental disclosure of cash flow information: |
|
|
| ||||
Interest paid | $ | 67 |
|
| $ | 2,330 |
|
Income taxes paid |
| 3 |
|
|
| 136 |
|
|
|
|
| ||||
Non-cash financing and investing activities: |
|
|
| ||||
|
|
|
| ||||
Conversion of Keep Well Notes to Common Stock and Warrants Issued | $ | 16,249 |
|
| $ | — |
|
Keep Well Note cancelled and funded Private Placement |
| 5,000 |
|
|
| — |
|
Common stock issued in connection with Keep Well Agreement |
| — |
|
|
| 1,249 |
|
Warrants issued in connection with Keep Well Notes and 2024 Notes |
| 11,034 |
|
|
| 1,002 |
|
Losses on extinguishments of debt with related party |
| 4,494 |
|
|
| — |
|
Write-off of debt issuance costs related to conversion of Keep Well Notes |
| 3,654 |
|
|
| — |
|
Write-off of debt issuance costs related to cancelled Keep Well Notes in Private Placement |
| 1,522 |
|
|
| — |
|
Financed insurance premiums |
| 2,103 |
|
|
| 2,474 |
|
Accrued debt issuance costs |
| 42 |
|
|
| 5 |
|
Finance lease and accrued purchases of property and equipment |
| 3 |
|
|
| 171 |
|
Common stock issued to settle contingent liability |
| — |
|
|
| 293 |
ONTRAK, INC.
Reconciliation of Non-GAAP Measures
(in thousands, except per share data)
Reconciliation of Operating Loss to EBITDA and Adjusted EBITDA | ||||||||||||||||
|
| Three Months Ended |
| Year Ended | ||||||||||||
|
| 2023 |
| 2022 |
| 2023 |
| 2022 | ||||||||
Operating loss |
| $ | (5,213 | ) |
| $ | (7,999 | ) |
| $ | (21,132 | ) |
| $ | (44,117 | ) |
Depreciation expense |
|
| 925 |
|
|
| 272 |
|
|
| 1,801 |
|
|
| 2494 |
|
Amortization expense (1) |
|
| 122 |
|
|
| 413 |
|
|
| 1,196 |
|
|
| 1,630 |
|
EBITDA |
|
| (4,166 | ) |
|
| (7,314 | ) |
|
| (18,135 | ) |
|
| (39,993 | ) |
Stock-based compensation expense |
|
| 608 |
|
|
| 1,250 |
|
|
| 2,948 |
|
|
| 7,532 |
|
Restructuring, severance and related costs (2) |
|
| — |
|
|
| — |
|
|
| 457 |
|
|
| 934 |
|
Adjusted EBITDA |
| $ | (3,558 | ) |
| $ | (6,064 | ) |
| $ | (14,730 | ) |
| $ | (31,527 | ) |
Reconciliation of Net Loss to Non-GAAP Net Loss; and Net Loss per Common Share to Non-GAAP Net Loss per Common Share | ||||||||||||||||
|
| Three Months Ended |
| Year Ended | ||||||||||||
|
|
| 2023 |
|
|
| 2022 |
|
|
| 2023 |
|
|
| 2022 |
|
Net loss |
| $ | (6,396 | ) |
| $ | (9,106 | ) |
| $ | (27,920 | ) |
| $ | (51,573 | ) |
Stock-based compensation expense |
|
| 608 |
|
|
| 1,250 |
|
|
| 2,948 |
|
|
| 7,532 |
|
Write-off of debt issuance costs (3) |
|
| — |
|
|
| — |
|
|
| — |
|
|
| 3,334 |
|
Restructuring, severance and related costs (2) |
|
| — |
|
|
| — |
|
|
| 457 |
|
|
| 934 |
|
Write-off of other asset |
|
| — |
|
|
| 259 |
|
|
| 100 |
|
|
| 259 |
|
Gain on change in fair value of warrant liability |
|
| (9 | ) |
|
| (12 | ) |
|
| (35 | ) |
|
| (133 | ) |
Gain on termination of operating lease (4) |
|
| — |
|
|
| — |
|
|
| (471 | ) |
|
| — |
|
Non-GAAP net loss |
|
| (5,797 | ) |
|
| (7,609 | ) |
|
| (24,921 | ) |
|
| (39,647 | ) |
Dividends on preferred stock - declared and undeclared |
|
| (2,238 | ) |
|
| (2,238 | ) |
|
| (8,954 | ) |
|
| (8,954 | ) |
Non-GAAP net loss attributable to common stockholders |
| $ | (8,035 | ) |
| $ | (9,847 | ) |
| $ | (33,875 | ) |
| $ | (48,601 | ) |
|
|
|
|
|
|
|
|
| ||||||||
Net loss per common share - basic and diluted |
| $ | (0.29 | ) |
| $ | (2.52 | ) |
| $ | (3.30 | ) |
| $ | (15.61 | ) |
Non-GAAP net loss per common share - basic and diluted |
|
| (0.27 | ) |
|
| (2.19 | ) |
|
| (3.04 | ) |
|
| (12.54 | ) |
Weighted-average common shares outstanding - basic and diluted |
|
| 29,950 |
|
|
| 4,505 |
|
|
| 11,159 |
|
|
| 3,877 |
|
(1) |
| Relates to operating and financing right-of-use assets and acquired intangible assets. |
(2) |
| Includes one-time severance and related benefit costs related to reduction in workforce plans announced in March 2023 and August 2022 as part of Company's continued cost savings measure. |
(3) |
| Relates to write-off of debt issuance costs on our 2024 Notes. |
(4) |
| Represents gain realized on derecognition of ROU operating asset and related lease liability due to early termination of the lease of the office space located in Santa Monica, CA in February 2023. |
Last Trade: | US$1.73 |
Daily Change: | -0.05 -2.81 |
Daily Volume: | 39,790 |
Market Cap: | US$5.540M |
November 13, 2024 November 06, 2024 September 11, 2024 September 05, 2024 August 29, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB